Last update July 25, 2017

ジサイクロミン塩酸塩

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Because of high protein-binding capacity, clinically significant excretion into breast milk is unlikely. However, both the mother and the infant would benefit of the use of a better-known alternative drug that would be safer while breastfeeding, especially in the neonatal period and in case of prematurity.

In spite of a low excretion into breast milk, it has been described a case of severe apnea in a 12 days old infant. A causal connection between those features and this drug has not been clearly defined (Briggs 2011, p. 410).

It is licensed for use in children from 6 months of age as intestinal antispasmodic and treatment of Familial Mediterranean Fever, so there would be less risky when used by the breastfeeding mother.

Alternatives

We do not have alternatives for ジサイクロミン塩酸塩.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

ジサイクロミン塩酸塩 is Dicycloverine in Japanese.

Is written in other languages:

ジサイクロミン塩酸塩 is also known as

Group

ジサイクロミン塩酸塩 belongs to this group or family:

Tradenames

Main tradenames from several countries containing ジサイクロミン塩酸塩 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 67 %
Molecular weight 346 daltons
Protein Binding 99 %
VD 3.7 l/Kg
Tmax 1 - 1.5 hours
1.8 - 10 hours
M/P ratio 2.2 -
Theoretical Dose 0.02 mg/Kg/d
Relative Dose 0.7 - 1.5 %
Ped.Relat.Dose 1 - 2 %

References

  1. Gerald G. Briggs, Roger K. Freeman, Sumner J. Yaffe. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Ninth edition. 2011 Full text (in our servers)
  2. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,972

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM